CSI Market
Sign In | Register

Miragen Therapeutics Inc (MGEN) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access MGEN Annual Cash Flow →
Tracking cash flow results across Miragen Therapeutics Inc to Sep 30 2019 helps illustrate how Jun 30 2025's cash generation has responded to changing business conditions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2025)
6 Months 		(Sep 30 2020) (Jun 30 2020) (Dec 31 2019) (Sep 30 2019)
Operating Activities
Income-100.74
Depreciation & amortization0.23
Amortization of Other Assets0.21
Accretion Expense0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation21.06
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Income taxes0.00
Unrealized Gain (Loss) on Investments0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable6.40
Increase (Decrease) in Accrued Liabilities-9.72
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-5.48
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net3.87
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-168.03
Investing Activities
Capital Expenditures-0.13
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities302.91
Payments to Acquire Marketable Securities-127.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities175.78
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock3.62
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock1.62
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities9.98
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-168.15
Total Cash Flow17.73
4 historic quarters locked

Sign in to unlock the full Miragen Therapeutics Inc cash flow history.

Sign In Create Free Account

About Viridian Therapeutics Inc De Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001590750-26-000018

Figures are derived from filed reports and may be restated. Historical data is subject to revision.